Izrael - hebrejščina - Ministry of Health

padagis israel agencies ltd, israel - temozolomide - קפסולות - temozolomide 100 mg - temozolomide - temozolomide - temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.

Izrael - hebrejščina - Ministry of Health

padagis israel agencies ltd, israel - temozolomide - קפסולות - temozolomide 100 mg - temozolomide - temozolomide - temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.

Izrael - hebrejščina - Ministry of Health

pfizer pharmaceuticals israel ltd - cytarabine 100 mg / 5 ml - powder for solution for inj/inf - cytarabine - for leukemia.

Izrael - hebrejščina - Ministry of Health

pharmalogic ltd - cytarabine 100 mg / 5 ml - solution for injection - cytarabine - for induction and maintenance of clinical remission in patients with acute myeloid leukemia, acute non-lymphoblastic leukemias, acute lymphoblastic leukemias, blast crises of chronic myeloid leukemia, diffuse histiocytic lymphomas ( non-hodgkin's lymphomas of high malignancy).

Izrael - hebrejščina - Ministry of Health

pharmalogic ltd - oxaliplatin 100 mg/vial - powder for concentrate for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : * adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour * treatment of advanced colorectal cancer.

Izrael - hebrejščina - Ministry of Health

novapharma ltd - oxaliplatin 100 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.- treatment of metastatic colorectal cancer.

Izrael - hebrejščina - Ministry of Health

perrigo israel agencies ltd - oxaliplatin 100 mg - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for:- adjuvant treatment of stage iii (duke’s c) colon cancer after complete resection of primary tumour.-treatment of metastatic colorectal cancer.

Izrael - hebrejščina - Ministry of Health

novartis pharma services ag - imatinib as mesylate 100 mg - capsules - imatinib - treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ - cml) in chronic phase, accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist).

Izrael - hebrejščina - Ministry of Health

bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 100 mg - dasatinib - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Izrael - hebrejščina - Ministry of Health

astra zeneca israel ltd - vandetanib 100 mg - film coated tablets - vandetanib - caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (mtc) in patients with unresectable locally advanced or metastatic disease. for patients in whom rearranged during transfection (ret) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision